Identification of a novel therapeutic target for head and neck squamous cell carcinomas: A role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway

International Journal of Cancer

Volumn 123, Issue 8, 2008, Pages 1816-1823

  Shimizu, Satoya ^a   Tsukada, Jun ^a   Sugimoto, Takashi ^a   Kikkawa, Naoko ^a   Sasaki, Keita ^a   Chazono, Hideaki ^a   Hanazawa, Toyoyuki ^a   Okamoto, Yoshitaka ^a   Seki, Naohiko ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Head and neck squamous cell carcinomas; Microarray; neurotensin; Neurotensin receptor 1

Indexed keywords

INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MARKER; MESSENGER RNA; NEUROTENSIN DERIVATIVE; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CARCINOMA CELL; CELL INVASION; CELL LINE; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; KAPLAN MEIER METHOD; LOG RANK TEST; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; ONCOGENE; OROPHARYNX CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; UNINDEXED SEQUENCE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 12; NEOPLASM INVASIVENESS; NEUROTENSIN; OSTEOPONTIN; RECEPTORS, NEUROTENSIN; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 51949107050     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23710     Document Type: Article

References (31)

1. Hardisson D. Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2003;260:502-8.
2. Fidler IJ. Cancer biology: invasion and metastasis. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical oncology, 2nd edn. New York: Churchill Livingstone, 2000. 29-53.
3. Fidler IJ, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 1994;13:209-22.
4. Song S, Wientjes MG, Gan Y, Au JL. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000;97:8658-63.
5. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006;25:435-57.
6. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 1973;248:6854-61.
7. Evers BM, Izukura M, Townsend CM, Jr, Uchida T, Thompson JC. Differential effects of gut hormones on pancreatic and intestinal growth during administration of an elemental diet. Ann Surg 1990;211:630-8.
8. Evers BM, Izukura M, Townsend CM, Jr, Uchida T, Thompson JC. Neurotensin prevents intestinal mucosal hypoplasia in rats fed an elemental diet. Dig Dis Sci 1992;37:426-31.
9. Jean-Pierre V, Jean M, Patrick K. Neurotensin and neurotensin receptors. Trends Pharmacol Sci 1999;20:302-9.
10. Frederique S, Patricia F. Molecular and cellular regulation of neurotensin receptor under acute and chronic agonist stimulation. Peptide 2006;27:2493-2501.
11. Thomas RP, Hellmich MR, Townsend CM, Jr, Evers BM. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocrinol Rev 2003;24:571-99.
12. Souaze F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, Gespach C, Gompel A, Forgez P. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res 2006;66:6243-9.
13. Ehlers RA, Zhang Y, Hellmich MR, Evers BM. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem Biophys Res Commun 2000;269:704-8.
14. Maoret JJ, Anini Y, Rouyer-Fessard C, Gully D, Laburthe M. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer 1999;80:448-54.
15. Gully D, Canton M, Boigegrain R, Jeanjean F, et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci USA 1993;90:65-9.
16. Zhao D, Kuhnt-Moore S, Zeng H, Wu JS, Moyer MP, Pothoulakis C. Neurotensin stimulates IL-8 expression in human colonic epithelial cells through Rho GTPase-mediated NF-kappa B pathways. Am J Physiol Cell Physiol 2003;284:C1397-C1404.
17. Leyton J, Garcia-Marin L, Jensen RT, Moody TW. Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells. Eur J Pharmacol 2002;442:179-86.
18. Dubuc I, Costentin J, Doulut S, Rodriguez M, Martinez J, Kitabgi P. JMV 449: a pseudopeptide analogue of neurotensin-(8-13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse. Eur J Pharmacol 1992;219:327-9.
19. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007;7:79-94.
20. Dal Farra C, Sarret P, Navarro V, Botto JM, Mazella J, Vincent JP. Involvement of the neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell lines. Int J Cancer 2001;92:503-9.
21. Gassmann P, Enns A, Haier J. Role of tumor cell adhesion and migration in organ-specific metastasis formation. Onkologie 2004;27:577-82.
22. He M, Rosen J, Mangiameli D, Libutti SK. Cancer development and progression. Adv Exp Med Biol 2007;593:117-33.
23. Rozengurt E. Neuropeptides as cellular growth factors: role of multiple signaling pathways. Eur J Clin Invest 1991;21:123-34.
24. Rozengurt E. Signal transduction pathways in the mitogenic response to G protein-coupled neuropeptide receptor agonists. J Cell Physiol 1998;177:507-17.
25. Rozengurt E. Neuropeptides as growth factors for normal and cancerous cells. Trends Endocrinol Metab 2002;13:128-34.
26. Haase C, Bergmann R, Oswald J, Zips D, Pietzsch J. Neurotensin receptors in adeno- and squamous cell carcinoma. Anticancer Res 2006;26:3527-33.
27. Vias M, Burtt G, Culig Z, Veerakumarasivam A, Neal DE, Mills IG. A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate 2007;67:190-202.
28. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000;6:4823-30.
29. Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006;42:760-7.
30. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N, Van Waes C. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999;26:119-29.
31. Wang X, Wang Q, Ives KL, Evers BM. Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin Cancer Res 2006;12:5346-55.